Conferences
ESMO 2024: Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer: An Ancillary Study of the PEACE-1 Phase 3 Trial
September 16, 2024
ESMO 2024: INSPIRE: Phase 2 Trial of Nivolumab 3mg/kg and Ipilimumab 1mg/kg in Molecularly Selected Patients with mCRPC
September 16, 2024
ESMO 2024: The Role of Cytoreductive Nephrectomy in the Immunotherapy Era
September 16, 2024
ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with mCRPC
September 16, 2024
New Data from TAR-200 Phase 2b SunRISe-1 Study Show 84 Percent Complete Response Rate in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
September 15, 2024
ESMO 2024: TAR-200 +/- Cetrelimab and Cetrelimab Alone in Patients with BCG-Unresponsive High-Risk NMIBC: Updated Results from SunRISe-1
September 15, 2024
ESMO 2024: Invited Discussant: Futibatinib Plus Pembrolizumab, Retrospective Assessment of Nectin-4 Expression, and Disitamab Vedotin
September 15, 2024
ESMO 2024: Pre-Treatment Risk Factors for Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients with Advanced Urothelial Carcinoma: Analysis of UNITE
September 15, 2024
ESMO 2024: Invited Discussant: Efficacy of SPLASH and UpFrontPSMA Trials
September 15, 2024